and trismus. As an acute presentation is unexpected therefore, clinical assessment in this case was difficult.
Skin lesions indistinguishable from those of porphyria cutanea tarda occur in about 1°of patients on maintenance haemodialysis.1 Usually there is no evidence of abnormal porphyrin metabolism,' but three cases in which true porphyria cutanea tarda developed during chronic haemodialysis have been reported.2 The primary enzyme defect is a decrease in hepatic uroporphyrinogen decarboxylase activity.3 We describe a patient with an inherited defect of this enzyme who developed the condition while receiving chronic haemodialysis.
Case report
A 16-year-old boy with chronic glomerulonephritis was started on chronic haemodialysis in August 1975. In August 1976 he noticed hyperpigmentation, skin fragility, and multiple bullae on his face and backs of his hands. At this time urine output was very low and the diagnosis of porphyria cutanea tarda was established by measuring porphyrins in plasma (table) and faeces (isocoproporphyrin:coproporphyrin ratio 1-2; normal less than 0-1). There was no family history of porphyria and no evidence of liver disease, and he was teetotal. Since August 1975 he had received aluminium hydroxide, methyldopa, propranolol, vitamin complex, iron-dextran (100 mg monthly), and six units of blood. From October 1976 dialysis was performed with a Haemodialyzer RP 6 HP using an acrylonitrile membrane (1-03 m2; 30 jLm), which reduced the plasma porphyrin concentration (table). The calculated dialysance for uroporphyrin was 797 ml/min. Skin fragility persisted and treatment with chloroquine (75 mg weekly for two months), which worsened his hypertension, and cholestyramine was unsuccessful.
In January 1979 serum ferritin was 878 ,ug/l (normal 10-250 ,ug/l).
The patient's uroporphyrinogen decarboxylase activity, measured in haemolysed whole blood after activation with dithiothreitol, using penta- carboxylate porphyrinogen III as substrate, was 17 2 pmol coproporphyrin/ min/mg haemoglobin (mean and range for 18 normal subjects: 24 8, 20-3-32-6 pmol/min/mg). His sister and mother had similar low enzyme activities, 17-1 and 17 2 pmol/min/mg respectively, whereas those of his brother (35 6 pmol/min/mg) and father (28 6 pmol/min/mg) were not low. Total urinary and faecal porphyrin excretion was normal in these relatives but his sister and mother showed increased urinary excretion of heptacarboxylic porphyrin, indicating subclinical porphyria cutanea tarda.
Comment
The occurrence of porphyria cutanea tarda during chronic haemodialysis for chronic renal failure is rare and the relation between these disorders is uncertain. In previous cases the cause of the uroporphyrinogen decarboxylase defect has not been determined.2 In our patient, as in a proportion of other patients with porphyria cutanea tarda,4 it appears to have been caused by inheritance of an autosomal dominant gene, the effect of which is expressed in the liver as well as in red cells.3 The enzyme defect, therefore, must have been present before the onset of renal disease. Thus chronic haemodialysis, like alcoholic liver disease with siderosis,3 may be associated with porphyria cutanea tarda because it is capable of making an otherwise occult enzyme defect clinically manifest. Why haemodialysis should have this effect is not clear. The iron overload that is common in patijnts undergoing haemodialysis5 may be a factor in precipitating the disease.2 Our patient received iron-dextran, and iron overload was certainly present after the onset of the porphyria. Alternatively, patients undergoing haemodialysis may produce or be subjected to compounds that affect hepatic haem synthesis.
Haemodialysis almost halved the concentration of porphyrins in the plasma of our patient, with nearly quantitative recovery in the dialysate and with little change in the porphyrin profile (table) . In contrast, Poh-Fitzpatrick et a12 were unable to lower plasma porphyrins by haemodialysis. This difference may be explained by our use of a high-permeability membrane. Despite regular haemodialysis, plasma concentrations remained high, and effective treatment of porphyria cutanea tarda in these patients is difficult. Our patient reacted adversely to a low dosage of chloroquine and depletion of iron stores by repeated venesection cannot be justified. 
